Chancery Keeps Alive Suit Over Repriced Anixa Stock Options
Law360 (June 14, 2019, 5:45 PM EDT) -- Class claims that Anixa Biosciences Inc. directors down-priced stock options held by insiders in 2017 while delaying a new patent award announcement that bumped up option values survived a Chancery Court dismissal challenge late Thursday.
Vice Chancellor Kathaleen S. McCormick’s ruling found arguments conceivable enough to reject dismissal of fiduciary duty breach and unjust enrichment claims filed by a stockholder on the company’s behalf against all five of the Anixa directors who were serving at the time of the repricing.
Also kept alive were the same claims against two of three executives sued who were serving when the options were repriced...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!